Arcutis Biotherapeutics announces results for Phase 2 trial of Zoryve

Arcutis Biotherapeutics (ARQT) announced topline results from the Integument-Infant Phase 2 study evaluating the safety, tolerability, and efficacy of Zoryve cream 0.05% in infants aged 3 months to less than 24 months with atopic dermatitis. Zoryve cream, a highly selective and potent topical phosphodiesterase 4 inhibitor, was well tolerated with a safety profile consistent with previous Zoryve clinical trials. Overall, the incidence of adverse events was low, with all being mild to moderate in severity. Zoryve cream improved the severity of disease and reduced the area of skin affected by atopic dermatitis, with 58% of participants achieving EASI-75 at Week 4.